0001209191-18-053536.txt : 20181002
0001209191-18-053536.hdr.sgml : 20181002
20181002213844
ACCESSION NUMBER: 0001209191-18-053536
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180928
FILED AS OF DATE: 20181002
DATE AS OF CHANGE: 20181002
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GALAKATOS NICHOLAS
CENTRAL INDEX KEY: 0001252522
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38670
FILM NUMBER: 181103610
MAIL ADDRESS:
STREET 1: THE JOHN HANCOCK TOWER
STREET 2: 200 CLARENDON STREET, 54TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Entasis Therapeutics Holdings Inc.
CENTRAL INDEX KEY: 0001724344
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 824592913
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (781) 810-0120
MAIL ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: Entasis Therapeutics Ltd
DATE OF NAME CHANGE: 20171204
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-09-28
0
0001724344
Entasis Therapeutics Holdings Inc.
ETTX
0001252522
GALAKATOS NICHOLAS
C/O ENTASIS THERAPEUTICS HOLDINGS INC.
35 GATEHOUSE DRIVE
WALTHAM
MA
02451
1
0
1
0
Common Stock
2018-09-28
4
C
0
361829
A
361829
I
See Footnote
Common Stock
2018-09-28
4
C
0
323341
A
685170
I
See Footnote
Common Stock
2018-09-28
4
C
0
412583
A
1170010
I
See Footnote
Common Stock
2018-09-28
4
P
0
453395
15.00
A
1623405
I
See Footnote
Series B Convertible Preferred Stock
2018-09-28
4
C
0
7500000
0.00
D
Common Stock
361829
0
I
See Footnote
Series B-1 Tranche A Convertible Preferred Stock
2018-09-28
4
C
0
6702213
0.00
D
Common Stock
323341
0
I
See Footnote
Series B-1 Tranche B Convertible Preferred Stock
2018-09-28
4
C
0
8552024
0.00
D
Common Stock
412583
0
I
See Footnote
Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
The reportable securities are held directly by Clarus Lifesciences III, L.P. ("Clarus III"). Clarus Ventures III GP, L.P. ("Clarus III GP") is the sole general partner of Clarus III. Clarus Ventures III, LLC ("Clarus III GP LLC") is the sole general partner of Clarus III GP. The Reporting Person, a director of the Issuer, is a managing director of Clarus III GP LLC. Each of Clarus III GP, Clarus III GP LLC and the Reporting Person may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Reporting Person disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.
This number includes an aggregate of 72,257 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018.
/s/ Jason Minio, Attorney-in-Fact
2018-10-02